STOCK TITAN

LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.

These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.

Positive

  • None.

Negative

  • None.
Insider JOHNSON JAMES A
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 28,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Options granted 28,000 options Stock Option (Right to Buy) grant on underlying common stock
Exercise price $9.54 per share Conversion or exercise price for the stock options
Expiration date April 8, 2036 Option expiration for the 28,000 granted options
Vesting period 24 months Monthly vesting on grant anniversaries, subject to continued service
Underlying shares 28,000 shares Common stock underlying the granted stock options
Options held after grant 28,000 options Total derivative holdings following the transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
2026 Equity Incentive Plan financial
"as defined in the Issuer's 2026 Equity Incentive Plan"
Service Provider financial
"subject to the optionee continuing to be a Service Provider"
vesting financial
"scheduled to vest monthly over a term of 24 months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JOHNSON JAMES A

(Last)(First)(Middle)
C/O LEONABIO, INC.
18706 NORTH CREEK PARKWAY, SUITE 104

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.5404/09/2026A28,000 (1)04/08/2036Common Stock28,000$028,000D
Explanation of Responses:
1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
/s/ Mark Worthington, Attorney in fact for James A. Johnson04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director James A. Johnson report on this Form 4?

James A. Johnson reported receiving a stock option grant for 28,000 shares of LeonaBio common stock. The options were awarded as compensation, not bought in the market, and give him the right to purchase shares at a fixed exercise price.

What are the key terms of James A. Johnson’s new stock options in LeonaBio (LONA)?

Johnson’s options cover 28,000 shares of common stock at an exercise price of $9.54 per share, expiring on April 8, 2036. These terms define how many shares he can buy, at what price, and until when.

How do the LeonaBio (LONA) stock options granted to James A. Johnson vest?

The options vest monthly over 24 months on the monthly anniversaries of the grant date. Vesting continues only while he remains a Service Provider as defined in LeonaBio’s 2026 Equity Incentive Plan, linking the award to ongoing service.

How many LeonaBio (LONA) stock options does James A. Johnson hold after this transaction?

After this transaction, Johnson holds 28,000 stock options directly, with underlying rights to acquire 28,000 common shares. This figure reflects his derivative holdings following the reported grant in the Form 4 data.

Is James A. Johnson’s LeonaBio (LONA) Form 4 transaction a market purchase or a compensation award?

The Form 4 shows a grant or award acquisition coded as transaction type A, indicating compensation rather than a market purchase. The exercise price is set at $9.54, and no cash-valued buy or sell transaction is reported.